PEMBROLIZUM/ BERAHYALURONIDASE ALFA-PMPH INJ,SOLN NEW
Clinical Criteria Summary
Exclusion Criteria
- Autoimmune disease
- Immunosuppression including corticosteroid equivalent to >10 mg per day of prednisone
- Primary immunodeficiency
- History of allogeneic hematopoietic stem cell or solid organ transplant
- Pregnancy (i.e. known pregnancy or positive pregnancy test)
- Breastfeeding
Inclusion Criteria
- Indication is FDA approved
- Off-label use supported by high-level published data
- Pembrolizumab and berahyaluronidase does not have an indication in classical Hodgkin Lymphoma or Primary Mediastinal Large B-Cell Lymphoma
Additional Inclusion Criteria
- Care is provided by a VA/VA Community Care oncology or hematology provider
- Goals of care and role of Palliative Care consult have been discussed and documented
- Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2
- Female patients of child-bearing potential and male patients with female partners of child-bearing potential: counseling provided on contraception and risks vs. benefits of treatment. Use effective contraception during therapy and for 4 months after the last dose.